BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30283446)

  • 1. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy.
    Roszik J; Ring KL; Wani KM; Lazar AJ; Yemelyanova AV; Soliman PT; Frumovitz M; Jazaeri AA
    Front Immunol; 2018; 9():2102. PubMed ID: 30283446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Markers of Angiogenesis, Lymphangiogenesis, and Epithelial-Mesenchymal Transition (Plasticity) in CIN and Early Invasive Carcinoma of the Cervix: Exploring Putative Molecular Mechanisms Involved in Early Tumor Invasion.
    Kurmyshkina O; Kovchur P; Schegoleva L; Volkova T
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor.
    Cocco E; Varughese J; Buza N; Bellone S; Glasgow M; Bellone M; Todeschini P; Carrara L; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Lockwood CJ; Santin AD
    BMC Cancer; 2011 Jun; 11():263. PubMed ID: 21693061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breaking the DNA damage response to improve cervical cancer treatment.
    Wieringa HW; van der Zee AG; de Vries EG; van Vugt MA
    Cancer Treat Rev; 2016 Jan; 42():30-40. PubMed ID: 26643553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenomic Identification for Predicting the Prognosis of Cervical Cancer Patients.
    Wang Q; Vattai A; Vilsmaier T; Kaltofen T; Steger A; Mayr D; Mahner S; Jeschke U; Hildegard Heidegger H
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prognostic signature based on immune-related genes for cervical squamous cell carcinoma and endocervical adenocarcinoma.
    Liu J; Wu Z; Wang Y; Nie S; Sun R; Yang J; Cheng W
    Int Immunopharmacol; 2020 Nov; 88():106884. PubMed ID: 32795900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma.
    Yang PM; Chou CJ; Tseng SH; Hung CF
    Oncotarget; 2017 Jul; 8(28):46145-46162. PubMed ID: 28526810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy.
    Ho CK; Kornaga EN; Klimowicz AC; Enwere EK; Dean M; Bebb GD; Phan T; Ghatage P; Magliocco AM; Lees-Miller SP; Doll CM
    Gynecol Oncol; 2017 Apr; 145(1):176-184. PubMed ID: 28131528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant expression of microRNA-26b and its prognostic potential in human cervical cancer.
    Luo M; Shen D; Wang W; Xian J
    Int J Clin Exp Pathol; 2015; 8(5):5542-8. PubMed ID: 26191262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical cancer patients that respond to chemoradiation therapy display an intense tumor infiltrating immune profile before treatment.
    Martins PR; Machado CMT; Coxir SA; de Oliveira AJ; Moreira TB; Campos LS; Alcântara R; de Paula SOC; de Oliveira Salles PG; Gollob KJ; Magalhães WCS
    Exp Mol Pathol; 2019 Dec; 111():104314. PubMed ID: 31654628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3.
    Fan Z; Cui H; Xu X; Lin Z; Zhang X; Kang L; Han B; Meng J; Yan Z; Yan X; Jiao S
    Oncotarget; 2015 Sep; 6(28):25266-80. PubMed ID: 26389681
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Zhu X; Zhang Y; Bai Y; Gu X; Chen G; Sun L; Wang Y; Qiao X; Ma Q; Zhu T; Bu J; Xue J; Liu C
    Int J Med Sci; 2020; 17(17):2773-2789. PubMed ID: 33162805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer.
    Li J; Xue X; Zhang Y; Ding F; Wu W; Liu C; Xu Y; Chen H; Ou Q; Shao Y; Li X; Wu F; Wu X
    Gynecol Oncol; 2023 Aug; 175():133-141. PubMed ID: 37356314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.
    Shu XR; Wu J; Sun H; Chi LQ; Wang JH
    Diagn Pathol; 2015 Sep; 10():177. PubMed ID: 26411419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
    D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
    Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis.
    Choi KH; Lee SW; Yu M; Jeong S; Lee JW; Lee JH
    J Gynecol Oncol; 2019 Jan; 30(1):e1. PubMed ID: 30479085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.
    Jensen DH; Dabelsteen E; Specht L; Fiehn AM; Therkildsen MH; Jønson L; Vikesaa J; Nielsen FC; von Buchwald C
    J Pathol; 2015 Aug; 236(4):505-16. PubMed ID: 25925492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of driver genes regulating immune cell infiltration in cervical cancer by multiple omics integration.
    Wen Y; Zhang S; Yang J; Guo D
    Biomed Pharmacother; 2019 Dec; 120():109546. PubMed ID: 31675687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target-based molecular signature characteristics of cervical adenocarcinoma and squamous cell carcinoma.
    Kim YW; Bae SM; Kim YW; Park DC; Lee KH; Liu HB; Kim IW; Jang CK; Ahn WS
    Int J Oncol; 2013 Aug; 43(2):539-47. PubMed ID: 23707988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer.
    Feng CH; Mell LK; Sharabi AB; McHale M; Mayadev JS
    Semin Radiat Oncol; 2020 Oct; 30(4):273-280. PubMed ID: 32828383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.